Pfizer (PFE) director reports phantom stock unit grant and 74,697 units held

Rhea-AI Filing Summary

Pfizer Inc. director reports phantom stock unit grant tied to board compensation. On 12/31/2025, a reporting person serving as a Pfizer director acquired 1,556.225 phantom stock units linked to Pfizer common stock at a price of $24.9 per unit. These units represent deferred director compensation, including dividend equivalents, that can be settled in cash or Pfizer common stock at the director's election after retiring from the Board of Directors. Following this transaction, the director beneficially owned 74,697.055 derivative securities in the form of phantom stock units, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quincey James

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units	(1)	12/31/2025		A		1,556.225		(2)	(2)	Common Stock	1,556.225	$24.9	74,697.055	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

	/s/ Shanice A. Reid, by power of atty., for James Quincey	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) disclose in this Form 4?

The filing reports that a Pfizer director acquired 1,556.225 phantom stock units linked to Pfizer common stock on 12/31/2025 as part of deferred director compensation.

How many Pfizer phantom stock units does the director own after the 12/31/2025 transaction?

After the reported transaction, the director beneficially owned 74,697.055 phantom stock units representing derivative securities tied to Pfizer common stock, held directly.

What is a phantom stock unit in the context of Pfizer (PFE)?

Each phantom stock unit represents one phantom share of Pfizer common stock. The value tracks the stock, but the units are typically settled in cash or shares rather than being actual stock until settlement.

How and when are Pfizer (PFE) director phantom stock units settled?

The units reported here represent deferred director compensation, including dividend equivalents, that are settled in cash or common stock at the director's election following retirement from Pfizer's Board of Directors.

Was the Pfizer (PFE) insider transaction direct or indirect ownership?

The Form 4 shows the 74,697.055 derivative securities, including the 1,556.225 units acquired on 12/31/2025, as owned in direct form by the reporting person.

What was the reference price for the Pfizer (PFE) phantom stock unit grant?

The reported phantom stock units were linked to Pfizer common stock at a price of $24.9 per unit as disclosed in the derivative securities table.